CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Ertugliflozin +1 moredrug
Likely dose
Ertugliflozin 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03416270
NCT03416270Phase 2Completed
CompareCT.gov

ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure: "ERADICATE-HF"

University Health Network, Toronto·interventional·Posted Jan 31, 2018·Updated May 6, 2025

In Brief

A Phase 2 clinical trial evaluating Ertugliflozin and Placebo for Type 2 Diabetes Mellitus and Heart Failure. Completed, enrolled 34 participants across 3 sites in 2 countries.

Detailed Summary

This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabetes and heart failure (T2D-HF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus, Heart Failure
CountriesCanada, Netherlands
CollaboratorsUniversity Medical Center Groningen, Merck Sharp & Dohme LLC, University of Toronto, Toronto General Hospital

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 31, 2018
Enrollment StartJun 28, 2018
Primary CompletionApr 14, 2021
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 8.4 years ago

Interventions

Ertugliflozindrug

Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks

Placebodrug

Placebo once daily for 12 weeks